Recently, it has been reported that PUS7 can serve as an underlying biomarker for glioma in a neurological tumor, glioblastoma [21], and up-regulated PUS7 increased Ψ modification in tRNA and decreased TYK2 translation can promote tumor progression through the interferon-STAT1 pathway. The gene discussed is TYK2; the disease is glioblastoma.